Can a daily pill slow aging? new trial tests GLYLO supplement in postmenopausal women

NCT ID NCT06813261

Recruiting now Disease control Sponsor: Buck Institute for Research on Aging Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This pilot study tests whether a dietary supplement called GLYLO can lower harmful compounds called AGEs in overweight or obese postmenopausal women aged 45-65. Participants take either GLYLO or a placebo for 24 weeks, and researchers measure changes in AGEs, insulin resistance, and physical/cognitive function. The goal is to see if this supplement can improve metabolic health and slow age-related decline.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLYLO (a combination of benfotiamine, vitamin B6, nicotinamide, alpha lipoic acid, and piperine)
What this could lead to: If it works, this could point toward a simple supplement to slow some aspects of aging and improve metabolic health in postmenopausal women.
What could go wrong: This is a very small, early pilot trial with only 30 participants. The supplement may not reduce AGEs or improve health outcomes, and results may not apply to all women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GEROSCIENCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GEROSCIENCE METABOLISM POSTMENOPAUSE

Contacts and locations

Locations

The Buck Institute for Research on Aging
RECRUITING

Novato, California, 94945, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.